Singapore markets closed
Straits Times Index
3,095.59 -6.62 (-0.21%) Nikkei
25,935.62 -457.42 (-1.73%) Hang Seng
21,859.79 -137.10 (-0.62%) FTSE 100
7,168.65 -0.63 (-0.01%) BTC-USD
19,274.59 -222.09 (-1.14%) CMC Crypto 200
420.84 +0.70 (+0.17%)
Orphazyme A/S (ORPHA.CO)
Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
At close: 04:59PM CEST
| Previous close | 1.8050 |
| Open | 1.8770 |
| Bid | 1.9900 x 0 |
| Ask | 2.0980 x 0 |
| Day's range | 1.8770 - 2.1000 |
| 52-week range | 1.1000 - 46.7000 |
| Volume | |
| Avg. volume | 200,430 |
| Market cap | 74.085M |
| Beta (5Y monthly) | 1.07 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -17.9400 |
| Earnings date | 20 Sept 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 108.00 |
- Zacks
KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M
KemPharm (KMPH) inks deal to acquire Orphazyme A/S, which will add to its portfolio the latter's pipeline candidate, arimoclomol, being developed for treating Niemann-Pick disease type C. Shares rise.
- Zacks
Orphazyme (ORPH) Up on Plans of NDA Resubmission for Rare Drug
Orphazyme (ORPH) is looking to resubmit its NDA for arimoclomol to the FDA for the treatment of Niemann-Pick disease type C in the United States. Shares rise.
- Zacks
All You Need to Know About Orphazyme AS Sponsored ADR (ORPH) Rating Upgrade to Buy
Orphazyme AS Sponsored ADR (ORPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
© 2022 Yahoo. All rights reserved.
